🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

SAI LIFE SCIENCES LIMITED SAILIFE NIFTY_SMALLNSEPHARMA

Healthcare · Diagnostics & Research · India
https://www.sailife.com
Company Profile ↓
₹1,273.60
+62.65% 1Y
Mkt Cap₹26,972.20 Cr
P/E77.52
P/B10.83
52W High₹1,273.60
52W Low₹782.15
Book Value₹117.28
EPS (TTM)₹16.43

Company Overview

Sai Life Sciences Limited operates as a contract research, development, and manufacturing organization (CRDMO) in India and internationally. It provides medicinal chemistry, pharmacokinetics, manufacturing, and contract development services. The company was formerly known as SAI Advantium Pharma Limited and changed its name to Sai Life Sciences Limited in July 2006. Sai Life Sciences Limited was incorporated in 1999 and is based in Hyderabad, India.

Why Investors Should Care

Healthy Capital Returns

Return on capital employed stands at 18.1%.

Consistent Profit Growth

Net profit has compounded at 226.9% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 22.4% CAGR over the past five years.

Healthy Margins

Maintains a net profit margin of 15.9%.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.12.

Recent Developments

  • Mar 2026 Revenue of ₹2,192.49 Cr (+29.4% YoY); net profit ₹348.91 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +29.4%, earnings +105.1%.
  • 5-Year Trend Long-term compounding — revenue CAGR 22.4%, profit CAGR 226.9%.

Growth & Price Performance

Compounded Sales Growth

5 Years:22.35%
1 Year:29.38%

Compounded Profit Growth

5 Years:226.89%
1 Year:105.08%

Stock Price Performance

1 Year:+62.65%
6 Months:+37.94%
3 Months:+30.98%
1 Month:+5.44%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 100% of range
₹782.15 ₹1,273.60
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)64.07 · Neutral
Price Performance
1M+5.44%
3M+30.98%
6M+37.94%
1Y+62.65%
Valuation vs Sector

P/E of 77.52 is above the sector median of 39.97 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 22.4% over 5 years.
  • Profit CAGR of 226.9% over 5 years.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Trading at a high P/E of 77.5.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
77.52
Industry PE
39.97
Forward P/E
51.92
PEG Ratio
-
Book Value
₹117.28
Price to Book
10.83
P/S
12.32
EV/EBITDA
42.82
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
22.35%
Profit 5Y
226.89%
Revenue (YoY)
29.38%
Earnings (YoY)
105.08%

Profitability & Returns

ROCE
18.10%
ROE
14.05%
ROA
9.62%
Profit Margin
15.91%
Op Margin
21.18%
Gross Margin
42.81%
EPS (Latest Qtr)
₹4.87
EPS (TTM)
₹16.43

Balance Sheet & Liquidity

Debt/Equity
0.12
Quick Ratio
1.51
Current Ratio
1.69
Debt
₹288.45 Cr
Total Assets
₹3,626.14 Cr
Current Assets
₹1,410.53 Cr
Working Capital
₹576.85 Cr

Ownership

Promoter Holding
37.96%
Chg in Prom Hold
-0.00%
FII / Inst Holding
42.43%
Chg in FII Hold
-0.08%

Financial Snapshot

Enterprise Value
₹26,972.20 Cr
Total Revenue (TTM)
₹2,192.49 Cr
EBITDA
₹672.29 Cr
Free Cash Flow
₹-83.83 Cr
Operating Cash Flow
₹509.13 Cr
Shares Outstanding
₹21.18 Cr
Gross Margin
42.81%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 SAILIFE SAI LIFE SCIENCES LIMITED NIFTY_SMALLNSEPHARMA 1,273.60 77.52 ₹26,972.20 Cr 0.00% 18.10% 14.05% 22.35% 226.89%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,948.80 40.77 ₹4.68 L Cr 0.83% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 7,315.50 75.61 ₹1.94 L Cr 0.44% 18.96% 15.32% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,952.20 87.70 ₹1.68 L Cr 0.78% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,981.00 66.51 ₹1.29 L Cr 0.23% 19.79% 20.48% 15.33% 33.34%
6 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,440.10 22.07 ₹1.16 L Cr 0.90% 14.86% 11.27% 7.23% 11.45%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,137.40 22.71 ₹1.14 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,494.30 21.42 ₹1.14 L Cr 0.72% 28.42% 23.76% 19.10% 131.46%
9 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 1,099.00 99.82 ₹1.07 L Cr 0.18% 12.57% 13.42% 22.37% 9.34%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 384.00 Cr439.00 Cr280.00 Cr396.00 Cr439.78 Cr579.51 Cr496.42 Cr537.00 Cr556.46 Cr602.14 Cr
Cost of Revenue ----253.76 Cr318.82 Cr301.73 Cr-300.94 Cr348.36 Cr
Gross Profit ----186.01 Cr260.69 Cr194.69 Cr-255.53 Cr253.78 Cr
Operating Expenses 287.00 Cr315.00 Cr254.00 Cr293.00 Cr100.35 Cr140.60 Cr111.48 Cr392.00 Cr111.75 Cr122.54 Cr
Operating Income 65.00 Cr94.00 Cr-5.00 Cr66.00 Cr85.66 Cr120.08 Cr83.21 Cr106.00 Cr143.78 Cr131.24 Cr
EBITDA 96.00 Cr125.00 Cr26.00 Cr102.00 Cr128.87 Cr167.17 Cr130.84 Cr146.00 Cr187.94 Cr192.36 Cr
Interest Expense 23.00 Cr21.00 Cr21.00 Cr21.00 Cr23.13 Cr10.89 Cr12.36 Cr9.00 Cr9.70 Cr7.83 Cr
Pretax Income 53.00 Cr76.00 Cr-18.00 Cr55.00 Cr71.65 Cr118.80 Cr80.75 Cr112.00 Cr134.17 Cr139.23 Cr
Tax Provision 13.25 Cr19.76 Cr4.50 Cr13.75 Cr17.80 Cr30.53 Cr20.29 Cr28.00 Cr33.79 Cr34.99 Cr
Net Income 40.00 Cr56.00 Cr-14.00 Cr42.00 Cr53.85 Cr88.27 Cr60.45 Cr84.00 Cr100.38 Cr104.24 Cr
Diluted EPS ----2.844.142.834.004.714.87

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 695.00 Cr726.00 Cr760.00 Cr-1,196.95 Cr1,456.47 Cr1,694.57 Cr2,192.49 Cr
Cost of Revenue ----878.76 Cr968.66 Cr1,014.88 Cr1,253.95 Cr
Gross Profit ----318.18 Cr487.81 Cr679.69 Cr938.54 Cr
Operating Expenses 520.00 Cr558.00 Cr593.00 Cr-241.36 Cr306.65 Cr412.60 Cr474.24 Cr
Operating Income 132.00 Cr113.00 Cr87.00 Cr-76.83 Cr181.16 Cr267.09 Cr464.30 Cr
EBITDA 176.00 Cr168.00 Cr167.00 Cr-192.90 Cr314.58 Cr442.44 Cr672.29 Cr
Interest Expense 24.00 Cr22.00 Cr33.00 Cr-77.06 Cr85.91 Cr76.16 Cr39.24 Cr
Pretax Income 113.00 Cr109.00 Cr82.00 Cr-16.41 Cr109.23 Cr227.70 Cr466.19 Cr
Tax Provision 39.55 Cr32.70 Cr20.50 Cr-6.42 Cr26.43 Cr57.57 Cr117.28 Cr
Net Income 73.00 Cr76.00 Cr61.00 Cr-9.99 Cr82.81 Cr170.13 Cr348.91 Cr
Diluted EPS ----0.483.988.6116.43

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 1,215.00 Cr1,410.00 Cr1,817.00 Cr-2,186.65 Cr2,275.14 Cr3,159.97 Cr3,626.14 Cr
Current Assets ----963.95 Cr945.11 Cr1,504.51 Cr1,410.53 Cr
Cash & Equivalents ----69.91 Cr23.66 Cr91.12 Cr81.91 Cr
Inventory ----139.53 Cr87.44 Cr118.86 Cr150.97 Cr
Receivables ----284.05 Cr256.18 Cr354.78 Cr373.62 Cr
Total Liabilities ----1,298.56 Cr1,299.99 Cr1,031.62 Cr1,142.45 Cr
Current Liabilities ----758.85 Cr739.90 Cr732.49 Cr833.68 Cr
Long Term Debt ----260.97 Cr277.25 Cr020.50 Cr
Total Debt 249.00 Cr304.00 Cr637.00 Cr-932.38 Cr927.66 Cr352.38 Cr288.45 Cr
Total Equity 719.00 Cr794.00 Cr862.00 Cr-888.09 Cr975.14 Cr2,128.36 Cr2,483.69 Cr
Shares Outstanding ----20.80 Cr20.80 Cr20.84 Cr21.18 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 129.00 Cr116.00 Cr-36.00 Cr-219.40 Cr263.09 Cr314.05 Cr509.13 Cr
Investing Cash Flow -158.00 Cr-262.00 Cr-260.00 Cr--101.78 Cr-192.38 Cr-536.66 Cr-395.41 Cr
Financing Cash Flow 268.00 Cr-4.00 Cr296.00 Cr--200.65 Cr-95.30 Cr301.43 Cr-123.68 Cr
Capital Expenditure -157.00 Cr-273.00 Cr-262.00 Cr--113.08 Cr-181.69 Cr-369.28 Cr-592.96 Cr
Free Cash Flow -28.00 Cr-157.00 Cr-298.00 Cr-106.33 Cr81.40 Cr-55.23 Cr-83.83 Cr
Net Change in Cash 239.00 Cr-150.00 Cr-1.00 Cr--83.03 Cr-24.59 Cr78.81 Cr-9.96 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % ----26.6%33.5%40.1%42.8%
Operating Margin % 19.0%15.6%11.4%-6.4%12.4%15.8%21.2%
Net Margin % 10.5%10.5%8.0%-0.8%5.7%10.0%15.9%
ROE % 10.2%9.6%7.1%-1.1%8.5%8.0%14.0%
ROCE % ----5.4%11.8%11.0%16.6%

Shareholding Pattern

Insiders
37.96%
Institutions
42.43%
Public Float
68.38%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for SAILIFE

Google News Fri, 22 May 2026

Sai Life Sciences (NSE:SAILIFE) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi7wFBVV95cUxObDhPZ01BODF5Y3dmeEFVaktqZkhsNmtIX3VGRXZyckxIak1LeUJ5VlRkejU3TWRnN2VPWkppejlKU2VWWU5PVzdSN2JGeFVJUGtlcGRxVzk0elR4NUkzV3IzcHowcjROdmNPR3BIcGJCdWtsUWtvQVVoRUpCRE15SDNlTDZra25xODNibl…

Google News Mon, 15 Jun 2026

41,936,680 Equity Shares of Sai Life Sciences Limited are subject to a Lock-Up Agreement Ending on 16-JUN-2026. - marketscreener.com

<a href="https://news.google.com/rss/articles/CBMi6AFBVV95cUxOcVRyNzQ1aENRUzVmYy13aVdabndUMlNkY2oxMWxlVFdVY2tRMXFXRDVGYVBfX244VEpnTTdsZDdrekNsSjBiVklyNTN5LXRuVXg3NXNXbFlobTFOZmNuaTJWNmM3cjItMmFjOWNxQW1mTGhHdlJoWTVKQ253WGVacm5sQjgtUXdEOXhSNT…

Google News Mon, 05 Jan 2026

Sai Life rallies 5%, hits all-time high; what's driving pharma stock? - Business Standard

<a href="https://news.google.com/rss/articles/CBMizAFBVV95cUxQblFSMVkyRGY2RW9wa0RGbzhQbmNvOEcySXNuMElZc3JQaG13TTlzX1IxM0x1amtVdlhpSXJ0dHE0T05LNlRWbF9hQ2g0c094ZEhDNTBwR2xlakdicWt4Rlo0dDhFSEp4cTg3VFd0TDdIYzZXUVQ2VUFtamJSckFNakVCTnFSQ0RFTGgtSF…

Google News Sun, 17 May 2026

Sai Life Sciences Limited (NSE:SAILIFE) Full-Year Results Just Came Out: Here's What Analysts Are Forecasting For This Year - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi7gFBVV95cUxPV3ZhZk9qVzRZMHZKMmNrUDN3dHlRcElmaUVSaXBTbDJsZGRGOE5lTWVUNG5hM2xsU3FMempBU3Z3YTJrRFlXdHVCRElfZW9ZVGhZdGZyNDRzbS1YbjRGMFc3X0EtTWQ0dDlZaWk1dWxnanJvY1BLTW5EZ3BEdF9tT2I4bHVfejV3ZU9xX2…

Google News Fri, 27 Feb 2026

Sai Life soars 25% in 5 weeks, hits record high in weak market; here's why - Business Standard

<a href="https://news.google.com/rss/articles/CBMi1AFBVV95cUxOaUxtbjJ0UDZTYzh1Q2g0UHk5US1YTDcxdlN0bDdQdU91ZXZCOVFsNGxmTURXc3RrM0duN3F2ZFdmWHVGWEMxbFRKR0ZrS1otZVdpNkRxdUhfdDR2RFd4UUVYZTlxVkhCMnJkWHctTHA2eDNMWm1fY1Q0am15Tk5pNUVDdHBXdjRhLWJsWV…

Google News ue, 26 Aug 2025

Sai Life Sciences Block Deal: Shares worth Rs 2,810 crore change hands; TPG Asia likely seller - Moneycontrol.com

<a href="https://news.google.com/rss/articles/CBMi7gFBVV95cUxPaGdhV3YyYUpES3NXRmc2NmFOSGo1dEZrM0Z3MW1heHZOMFdsakxVakU5TEt6Tm5teVloRjNDR3lwcU5CSVdvR0laN0hNTGlOZFFNUmxxSlNvTklXbF9vTVBUTlowcG1obml4aDZIOFdCMEZJYkVEWFA5RFVlbldaNXBCYU1kMXlZU3RHVW…

SAILIFE — Frequently Asked Questions

What is the current share price of SAI LIFE SCIENCES LIMITED (SAILIFE)?

As of 2026-07-15 09:52 IST, SAI LIFE SCIENCES LIMITED (SAILIFE) trades at ₹1,273.60 on NSE. Its 52-week range is ₹782.15 to ₹1,273.60.

What is the market capitalisation of SAILIFE?

SAI LIFE SCIENCES LIMITED (SAILIFE) has a market capitalisation of ₹26,972.20 Cr on NSE.

What is the P/E ratio of SAILIFE?

SAILIFE trades at a trailing price-to-earnings (P/E) ratio of 77.52. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 10.83.

What is the return on equity (ROE) of SAILIFE?

SAILIFE has a return on equity (ROE) of 14.05%. Its return on capital employed (ROCE) is 18.10%.

Is SAILIFE a good stock to buy?

This page provides a data-driven analysis of SAI LIFE SCIENCES LIMITED (SAILIFE), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space